Ronald Asbury Andrews - May 7, 2021 Form 4 Insider Report for OncoCyte Corp (OCX)

Role
Chief Executive Officer, Director
Signature
/s/ Ronald Andrews
Stock symbol
OCX
Transactions as of
May 7, 2021
Transactions value $
$0
Form type
4
Date filed
7/2/2021, 01:59 PM
Next filing
Jul 2, 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Options Exercise $0 +106K +93.42% $0.00 220K May 7, 2021 Direct
transaction OCX Common Stock, no par value Tax liability $0 -25.9K -11.76% $0.00 194K Jun 30, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Restricted Stock Units Options Exercise $0 -106K -100% $0.00* 0 May 7, 2021 Common Shares 106K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 106,221 Restricted Stock Units.
F2 Restricted Stock Units vested on May 7, 2021.